Impact of the Oral Orexin Receptor 2 Agonist TAK-994 on Sustained Attention in Patients with Narcolepsy Type 1: Exploratory Results from a Phase 2 Study (P11-9.012)
Yves Dauvilliers, Giuseppe Plazzi, Elena Koundourakis, Yeting Du, Christian von Hehn, Dmitri Volfson, Robert D. Latzman et Brian Harel
Impact of the Oral Orexin Receptor 2 Agonist TAK-994 on Sustained Attention in Patients with Narcolepsy Type 1: Exploratory Results from a Phase 2 Study (P11-9.012)